Researchers find lower lung function after inhaler change.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
FDA approved the first generic of a popular inhaler to treat asthma and chronic obstructive pulmonary disease
Certain groups expressed “deep concern” over FDA allowing an OTC asthma inhaler to be sold again after it was removed from the market 7 years ago. Here’s why.
A novel treatment for patients with moderate-to-severe asthma is now on the market.
The FDA’s Pulmonary-Allergy Drugs Advisory Committee recently recommended approval of GlaxoSmithKline Plc's drug mepolizumab (Nucala) for severe asthma patients 18 and older.
New data from Phase III trials showed that the addition of tiotropium Respimat in adult patients with mild, moderate and severe asthma who continue to experience symptoms despite the use of maintenance therapies improved lung function. Boehringer Ingelheim recently presented the new data on investigational tiotropium delivered via Respimat® inhaler at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Houston, Texas.